133242-30-5

Basic information

• Product Name: Landiolol
• Synonyms: [(4S)-2,2-Dimethyl-1,3-dioxolan-4-yl]methyl 3-[4-[(2S)-2-hydroxy-3-[2-(morpholine-4-carbonylamino)ethylamino]propoxy]phenyl]propanoate;Landiolol;((S)-2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-(4-((S)-2-hydroxy-3-((2-(morpholine-4-carboxamido)ethyl)amino)propoxy)phenyl)propanoate;Benzenepropanoic acid, 4-[(2S)-2-hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]-, [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl ester
• CAS NO: 133242-30-5
• Molecular Formula: C₂₅H₃₉N₃O₈
• Molecular Weight: 509.59
• EINECS: 1592732-453-0
• Mol File: 133242-30-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 727.513 °C at 760 mmHg
• Flash Point: 393.786 °C
• Appearance: /
• Density: 1.201 g/cm³
• CAS DataBase Reference: Landiolol(CAS DataBase Reference)
• NIST Chemistry Reference: Landiolol(133242-30-5)
• EPA Substance Registry System: Landiolol(133242-30-5)

Safety Data

• Hazardous Substances Data: 133242-30-5(Hazardous Substances Data)

Usage

Description

Landiolol, also known as Onoact, is an ultra-short-acting, cardioselective beta-adrenergic blocker synthesized from 3-(4-hydroxyphenyl)propionic acid. It is more cardioselective than esmolol and has shown greater efficiency in reducing heart rate and ventricular contraction in anesthetized dogs. Landiolol has a rapid onset of action and is rapidly hydrolyzed to inactive metabolites, resulting in an ultra-short half-life and allowing for rapid termination of drug effect if side effects occur.

Uses

Used in Cardiology:
Landiolol is used as an intravenous infusion for the treatment of tachyarrhythmia during surgery. It is effective against a variety of arrhythmias, including atrial fibrillation, paroxysmal supraventricular tachycardia, ventricular tachycardia, and premature complexes.
Used in Pharmaceutical Industry:
Landiolol is used as an active pharmaceutical ingredient for the development of medications targeting cardiovascular conditions, specifically tachyarrhythmias. Its ultra-short half-life and rapid onset of action make it a valuable asset in the management of heart rate and rhythm during surgical procedures.

Originator

Ono Pharmaceutical (Japan)

InChI:InChI=1/C25H39N3O8.ClH/c1-25(2)35-17-22(36-25)21(14-23(30)32-3)18-4-6-20(7-5-18)34-16-19(29)15-26-8-9-27-24(31)28-10-12-33-13-11-28;/h4-7,19,21-22,26,29H,8-17H2,1-3H3,(H,27,31);1H/t19-,21?,22+;/m0./s1

Upstream product

• 1398109-46-0 (S)-(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-(4-((2R)-3-chloro-2-hydroxypropoxy)phenyl)propanoate 
• 154467-16-0 N-(2-aminoethyl)-4-morpholine carboxamide oxalic acid 
• 88017-03-2 2-(morpholine-4-carboxamido)ethanamino hydrochloride 
• 144256-11-1 3-(4-hydroxyphenyl)propionic acid [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl ester 
• 144256-12-2 2,2-dimethyl-1,3-dioxolan-4S-ylmethyl 3-<4-<2(S),3-epoxypropoxy>phenyl>propionate 
• 110-91-8 morpholine 
• 23735-43-5 (S)-1-O-tosyl-2,3-O-isopropylideneglycerol 
• 93605-74-4 4-[(1H-imidazol-1-yl)carbonyl]morpholine 
• 501-97-3 4-hydroxyphenylpropionic acid 
• 69630-16-6 N-(2-aminoethyl)-4-morpholine carboxamide 

Downstream Products

• 144481-98-1 Landiolol hydrochloride 
• 1253907-79-7 landiolol hydrochloride 

Relevant articles and documents

Method for preparing landiolol hydrochloride

The invention belongs to the field of pharmaceutical chemicals, and particularly relates to an improved method for preparing landiolol and a compound shown as a formula 8. The compound shown as the formula 8 is prepared by reacting a compound shown as a formula 7 with AH (organic amine). The invention also relates to compounds of general formula 7.

Preparation method of landiolol hydrochloride

The invention provides a preparation method of landiolol hydrochloride. The preparation method utilizes cheap and easily available raw materials. A key reaction utilizes a phase transfer catalysis method so reaction time is shortened. The preparation meth

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.